Treatment effect variability in brain stimulation across psychiatric disorders: A meta-analysis of variance.

Bipolar disorder Heterogeneity in treatment response Noninvasive brain stimulation Obsessive–compulsive disorder Personalized treatment Schizophrenia spectrum disorder Transcranial direct current stimulation Transcranial magnetic stimulation Unipolar and bipolar depression

Journal

Neuroscience and biobehavioral reviews
ISSN: 1873-7528
Titre abrégé: Neurosci Biobehav Rev
Pays: United States
ID NLM: 7806090

Informations de publication

Date de publication:
05 2021
Historique:
received: 08 06 2020
revised: 26 10 2020
accepted: 29 11 2020
pubmed: 23 1 2021
medline: 29 6 2021
entrez: 22 1 2021
Statut: ppublish

Résumé

Noninvasive brain stimulation methods such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are promising add-on treatments for a number of psychiatric conditions. Yet, some of the initial excitement is wearing off. Randomized controlled trials (RCT) have found inconsistent results. This inconsistency is suspected to be the consequence of variation in treatment effects and solvable by identifying responders in RCTs and individualizing treatment. However, is there enough evidence from RCTs that patients respond differently to treatment? This question can be addressed by comparing the variability in the active stimulation group with the variability in the sham group. We searched MEDLINE/PubMed and included all double-blinded, sham-controlled RCTs and crossover trials that used TMS or tDCS in adults with a unipolar or bipolar depression, bipolar disorder, schizophrenia spectrum disorder, or obsessive compulsive disorder. In accordance with the PRISMA guidelines to ensure data quality and validity, we extracted a measure of variability of the primary outcome. A total of 130 studies with 5748 patients were considered in the analysis. We calculated variance-weighted variability ratios for each comparison of active stimulation vs sham and entered them into a random-effects model. We hypothesized that treatment effect variability in TMS or tDCS would be reflected by increased variability after active compared with sham stimulation, or in other words, a variability ratio greater than one. Across diagnoses, we found only a minimal increase in variability after active stimulation compared with sham that did not reach statistical significance (variability ratio = 1.03; 95% CI, 0.97, 1.08, P = 0.358). In conclusion, this study found little evidence for treatment effect variability in brain stimulation, suggesting that the need for personalized or stratified medicine is still an open question.

Identifiants

pubmed: 33482243
pii: S0149-7634(20)30676-X
doi: 10.1016/j.neubiorev.2020.11.033
pii:
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

54-62

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Stephanie Homan (S)

University Hospital of Psychiatry Zurich, Zurich, Switzerland; University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland. Electronic address: stephanie.homan@bli.uzh.ch.

Whitney Muscat (W)

Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA; Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA; Department of Psychiatry, Zucker School of Medicine at Northwell/Hofstra, Hempstead, NY, USA.

Andrea Joanlanne (A)

Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA; Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA; Department of Psychiatry, Zucker School of Medicine at Northwell/Hofstra, Hempstead, NY, USA.

Nikolaos Marousis (N)

University Hospital of Psychiatry Zurich, Zurich, Switzerland.

Giacomo Cecere (G)

University Hospital of Psychiatry Zurich, Zurich, Switzerland.

Lena Hofmann (L)

University Hospital of Psychiatry Zurich, Zurich, Switzerland.

Ellen Ji (E)

University Hospital of Psychiatry Zurich, Zurich, Switzerland.

Maria Neumeier (M)

University Hospital of Psychiatry Zurich, Zurich, Switzerland.

Stefan Vetter (S)

University Hospital of Psychiatry Zurich, Zurich, Switzerland.

Erich Seifritz (E)

University Hospital of Psychiatry Zurich, Zurich, Switzerland.

Thomas Dierks (T)

University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.

Philipp Homan (P)

University Hospital of Psychiatry Zurich, Zurich, Switzerland; Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA; Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA; Department of Psychiatry, Zucker School of Medicine at Northwell/Hofstra, Hempstead, NY, USA. Electronic address: philipp.homan@bli.uzh.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH